Abuse, DrugPhase 1NCT03757559
A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
A Phase 1 study testing Cebranopadol 100 micrograms, Cebranopadol 400 micrograms and Hydromorphone hydrochloride 4 milligrams in people with Abuse, Drug, run by Tris Pharma, Inc. at 1 site in Canada.
Trial summary
The primary objective of this study was to evaluate the abuse potential of single doses of cebranopadol (GRT6005) relative to hydromorphone (immediate-release formulation [IR] and placebo in 48 non-dependent recreational opioid users. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Abuse, Drug
- What is being tested?
- Cebranopadol 100 micrograms, Cebranopadol 400 micrograms and Hydromorphone hydrochloride 4 milligrams
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 226 participants
- Where
- 1 siteCanada
- Study dates
- 15 Apr 2013to 8 Mar 2014
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Informed consent signed.
- Male and female, aged 18 years to 55 years, inclusive.
- History of recreational opioid use (defined as non-therapeutic use at least 10 times in the participant's lifetime and at least once in the last 12 weeks prior to the Enrollment Visit).
- Body mass index between 19 kilograms per square meter and 32 kilograms per square meter inclusive, with a body weight of not less than 50 kilograms at enrollment.
- Participants must be in good health as determined by medical history, physical examination, 12-lead electrocardiogram (ECG), and vital signs (pulse rate, systolic blood pressure and diastolic blood pressure, respiratory rate, and oxygen saturation using pulse oximetry) at enrollment.
- Adequate contraception is being used or women of non-childbearing potential may be enrolled if surgically sterile (i.e., after hysterectomy) or post-menopausal for at least 2 years (based on participant's report).
Show all 10Show fewer
- For women of childbearing potential: A medically acceptable and highly effective method of birth control is defined as any form of contraception with a low failure rate defined as less than 1 percent per year. For example:
- Hormonal contraceptives for at least 8 weeks prior to the Enrollment Visit and at least until 4 weeks after the Final Examination.
- An intra-uterine device. Additional barrier contraception should be used by the partner for the duration of the study, defined as from the time of the Enrollment Visit until 4 weeks after the Final Examination. A single barrier method alone is not acceptable.
- For men: Participants must be willing to use medically acceptable and highly effective methods of birth control. Participants must be willing to use barrier contraception (condom) during sexual intercourse with females from the first administration of investigational medicinal product (IMP) until 4 weeks after the Final Examination. Participants must be willing to take care that their female sexual partner uses at least 1 additional method of contraception with a low failure rate defined as less than 1 percent per year (e.g., hormonal contraceptives, diaphragm) during this time frame. A single barrier method alone is not acceptable.
Who cannot join
- Current substance dependence (except nicotine and caffeine dependence) as defined by the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV).
- Unwillingness or inability to abstain from recreational drug use for the duration of the study.
- Positive or missing alcohol breath test at enrollment.
- Participants attempting to discontinue their recreational drug use or who had been in a drug rehabilitation program in the 12 months prior to enrollment.
- Current consumption of more than 20 cigarettes per day or inability to abstain from smoking (or use of any nicotine-containing substance) for at least 26 hours.
- Participation in another clinical study within 30 days prior to enrollment that resulted in the administration of at least 1 dose of IMP.
Show all 55Show fewer
- Diseases or conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- Prolongation of corrected QT interval (Fridericia) (QTcF) (after repeated assessment) at enrollment, i.e., above 450 milliseconds, or presence of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia), or use of concomitant medications that prolong QT interval.
- History of orthostatic hypotension or other cardiovascular diseases.
- Any clinically significant disease that in the investigator's opinion may affect efficacy or safety assessments or may compromise the participant's safety during study participation, e.g., significant pulmonary, gastrointestinal, cardiac, endocrine, metabolic, neurological, or psychiatric disorders.
- Definite or suspected history of drug allergy or hypersensitivity to opioids or naloxone.
- Use of forbidden medication within 2 weeks prior to enrollment into this study.
- Any contraindication for naloxone or hydromorphone immediate-release (IR) administration.
- Not able to abstain from consumption of:
- Beverages or food containing caffeine (tea, coffee, cola, chocolate, etc.) or alcohol from 2 days prior to each Day 1 until discharge from the ward.
- Beverages or food containing quinine (e.g., bitter lemon, tonic water) from 1 week before Day 1 of the Qualification Phase until the Final Examination.
- Grapefruit juice (sweet or sour) or Seville oranges from 1 week before Day 1 of the Qualification Phase until the Final Examination.
- Pregnant or breastfeeding women, or missing pregnancy test.
- Blood loss of 500 milliliters or more within 4 weeks before enrollment in this study, including blood donation. Planned blood donations during the study and up to 12 weeks after the Final Examination.
- History of seizure disorder and/or epilepsy or any condition associated with a significant risk for seizure disorder or epilepsy at the Enrollment Visit at the discretion of the investigator.
- Known or suspected of not being able to comply with the study protocol.
- Not able to communicate meaningfully with the investigator or study site staff.
- Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.
- Positive naloxone challenge on Day -1 of the Qualification Phase.
- Use of forbidden medication since the Enrollment Visit
- Positive or missing urine pregnancy test.
- Positive or missing alcohol breath test.
- Positive or missing urine drug of abuse screen result, except for cannabinoids (tetrahydrocannabinol [THC]; due to slow release from adipose), which must be negative, stable, or decreasing. If THC is not negative, stable, or decreasing, inclusion will be at the discretion of the investigator, in consultation with the sponsor.
- Positive or missing viral serology, i.e., human immunodeficiency virus Type 1 and Type 2 antibodies and antigen, hepatitis B surface antigens, antibodies to hepatitis B core antigen and immunoglobulin M antibody to hepatitis B core antigen, and hepatitis C virus antibodies, based on sample taken at the Enrollment Visit.
- Any abnormal laboratory values or any clinically relevant out-of-range values for safety laboratory parameters (clinical chemistry, clotting, hematology, and urinalysis) based on sample taken at the Enrollment Visit, as judged by the investigator.
- Blood donation or acute loss of blood (more than 100 milliliters) since the enrollment excluding blood samples required by the protocol.
- Any relevant deterioration in the health of the participant that could alter the benefit/risk assessment for the participant, including adverse events, laboratory parameters, vital signs, or other safety parameters (e.g., ECGs).
- Failure to comply with study requirements, e.g., intake of forbidden medications, consumption of alcohol, etc., considered by the investigator to affect participant safety or interfere with the integrity of the study.
- Uncooperative participants or participants who refused to continue in the study.
- Withdrawal of informed consent.
- Any contraindication for naloxone or hydromorphone IR administration.
- Discontinuation criteria for Day 1 (Treatment Phase):
- Failure to successfully fulfill any of the following criteria based on the qualification period prior to the first treatment period (Treatment Period 1, Day -1):
- Peak scores (Emax) in response to hydromorphone greater than that of placebo on (at this moment) Drug Liking VAS (difference of at least 15 points).
- Acceptable responses to placebo and hydromorphone on visual analog scale (VAS) for (at this moment) Drug Liking, High, Good Effects, Overall Drug Liking, Take Drug Again, and Feeling Sick, as judged by the investigator or designee and sponsor.
- The ability to tolerate hydromorphone, as judged by the investigator based on available safety data (e.g., respiratory rate greater than or equal to 8 breaths per minute and no vomiting).
- General behavior suggestive that they could successfully complete the study, as judged by the investigator.
- Positive or missing urine pregnancy test.
- Positive or missing alcohol breath test.
- If a participant tests positive for other drugs of abuse, the urine drug screen can be repeated and/or the participant rescheduled at the discretion of the investigator or designee, in consultation with the sponsor.
- Blood donation or acute loss of blood (more than 100 milliliters) since the Enrollment Visit excluding blood samples required by the protocol.
- Any relevant deterioration in the health of the participant that could alter the benefit/risk assessment for the participant, including adverse events, laboratory parameters, vital signs, or other safety parameters (e.g., ECG).
- Failure to comply with study requirements, e.g., intake of forbidden medications, consumption of alcohol, etc., considered by the investigator to affect participant safety or interfere with the integrity of the study.
- Uncooperative participants or participants who refused to continue in the study.
- Withdrawal of informed consent.
- Not able to use adequate contraception as defined in Inclusion Criterion 6.
- Not able to abstain from consumption of:
- Beverages or food containing quinine (e.g., bitter lemon, tonic water).
- Grapefruit juice (sweet or sour) or Seville oranges.
- Beverages or food containing caffeine (tea, coffee, cola, chocolate, etc.) or alcohol.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Single-dose, Nested-randomized, Double-blind, Double-dummy, Placebo- and Active-controlled Crossover Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
The primary objective of this study was to evaluate the abuse potential of single doses of cebranopadol (GRT6005) relative to hydromorphone (immediate-release formulation [IR] and placebo in 48 non-dependent recreational opioid users.
Secondary objectives were to evaluate the abuse potential of hydromorphone IR compared to placebo (trial validation), to evaluate the safety and tolerability of single doses of cebranopadol (200, 400, and 800 micrograms), and to evaluate pharmacokinetics (PK) of cebranopadol and optionally some of its metabolites.
Read the detailed description
The study comprised an Enrollment Visit, a Qualification Phase, a Treatment Phase with 7 double-blind treatment periods for each participant, and a Final Examination.
In the Qualification Phase, all participants completed a naloxone challenge test to confirm that they were not opioid-dependent. The Objective Opioid Withdrawal Scale was used to record the signs or symptoms of withdrawal observed during the naloxone challenge test. Following the naloxone challenge test, participants received a single oral dose of hydromorphone immediate-release (IR) 12 milligrams (mg) and placebo in a double-blinded, randomized crossover manner to ensure that they could discriminate between an active drug and placebo and could tolerate hydromorphone IR 12 mg. After a washout phase of at least 3 days, participants could continue with the Treatment Phase.
In the Treatment Phase, each participant received single oral doses of the 7 different investigational medicinal products (IMPs) (Treatment A to Treatment G) in 7 sequential treatment periods. The treatment sequences per participant were randomly assigned, except for one administration of placebo (Treatment G) which always followed the highest dose of cebranopadol (Treatment C). Each IMP administration was given under fasted conditions and was separated by a washout period of at least 14 days.
Participants were confined to the study site from Day -1 until 48 hours after the first IMP administration in the Qualification Phase and from Day -1 until 56 hours after the IMP administration in the treatment periods. Pharmacodynamic assessments and blood sampling for pharmacokinetics were performed from pre-dose until 56 hours post-dose in each treatment period.
The Final Examination was conducted 5 days to 10 days after the discharge from the last treatment period or upon early discontinuation from the study.
- Conditions
- Abuse, Drug
- Being tested
- Cebranopadol 100 micrograms, Cebranopadol 400 micrograms, Hydromorphone hydrochloride 4 milligrams, Placebo matching hydromorphone, Placebo matching cebranopadol
- Keywords
- Cebranopadol, Hydromorphone, Drug liking
- Medical subject headings
- Substance-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cebranopadol 100 microgramsDrug
Tablets were taken under fasted conditions with non-carbonated water.
Cebranopadol 400 microgramsDrug
Tablets were taken under fasted conditions with non-carbonated water.
Hydromorphone hydrochloride 4 milligramsDrug
Also called Dilaudid (Trade Mark) 4 mg
Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
Placebo matching hydromorphoneDrug
Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
Placebo matching cebranopadolDrug
Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
| Study group | Role | What they receive |
|---|---|---|
| Cebranopadol 200 micrograms (Treatment A) | Experimental | Cebranopadol 200 micrograms (low dose): Participants took 2 tablets (cebranopadol 100 micrograms) as a single dose.
In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose. Receives: Drug: Cebranopadol 100 micrograms; Drug: Placebo matching hydromorphone |
| Cebranopadol 400 micrograms (Treatment B) | Experimental | Cebranopadol 400 micrograms (medium dose): Participants took 2 tablets (cebranopadol 400 micrograms plus matching placebo) as a single dose.
In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose. Receives: Drug: Cebranopadol 400 micrograms; Drug: Placebo matching hydromorphone |
| Cebranopadol 800 micrograms (Treatment C) | Experimental | Cebranopadol 800 micrograms (high dose): Participants took 2 tablets containing cebranopadol 400 micrograms as a single dose.
In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose. Receives: Drug: Cebranopadol 400 micrograms; Drug: Placebo matching hydromorphone |
| Hydromorphone IR 8 milligrams (Treatment D) | Active comparator | Hydromorphone immediate-release (IR) 8 milligrams: Participants took 4 capsules (2 capsules of hydromorphone hydrochloride 4 mg plus 2 placebo capsules) as a single dose.
In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose. Receives: Drug: Hydromorphone hydrochloride 4 milligrams; Drug: Placebo matching cebranopadol |
| Hydromorphone IR 16 milligrams (Treatment E) | Active comparator | Hydromorphone immediate-release (IR) 16 milligrams: Participants took 4 capsules of hydromorphone hydrochloride 4 mg as a single dose.
In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose. Receives: Drug: Hydromorphone hydrochloride 4 milligrams; Drug: Placebo matching cebranopadol |
| Placebo (Treatment F) | Placebo comparator | Placebo: Participants took 4 placebo capsules matching hydromorphone capsules as a single dose.
In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose. Receives: Drug: Placebo matching hydromorphone; Drug: Placebo matching cebranopadol |
| Placebo (Treatment G) | Placebo comparator | Placebo (following Treatment C): Participants took 2 placebo tablets matching cebranopadol tablets as a single dose.
In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose. Receives: Drug: Placebo matching hydromorphone; Drug: Placebo matching cebranopadol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Drug Liking (at this moment)
Visual analog scale (VAS) rating; Question text: At this moment, my liking for this drug is ...; Bipolar response anchors: 0 (Strong disliking), 50 (Neither like nor dislike), 100 (strong liking).
Measured: At 16 distinct time points between 30 minutes and 56 hours after drug intake
Secondary outcomes (16)
Any Drug Effects
Visual analog scale (VAS) rating; Question text: I can feel any drug effect. Unipolar response anchors: 0 (Definitely not) to 100 (Definitely so).
Measured: At 16 distinct time points between 30 minutes and 56 hours after drug intake
Good Drug Effects
Visual analog scale (VAS) rating; Question text: I can feel good drug effects; Unipolar response anchors: 0 (Definitely not) to 100 (Definitely so).
Measured: At 16 distinct time points between 30 minutes and 56 hours after drug intake
Bad Drug Effects
Visual analog scale (VAS) rating; Question text: I can feel bad drug effects; Unipolar response anchors: 0 (Definitely not) to 100 (Definitely so).
Measured: At 16 distinct time points between 30 minutes and 56 hours after drug intake
High
Visual analog scale (VAS) rating; Question text: I am feeling high; Unipolar response anchors: 0 (Definitely not) to 100 (Definitely so).
Measured: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Take Drug Again
Visual analog scale (VAS) rating; Question text: I would take this drug again; Unipolar response anchors: 0 (Definitely not) to 100 (Definitely so).
Measured: At 12, 24, and 56 hours aft drug intake
Feeling Sick
Visual analog scale (VAS) rating: Question text: I am feeling sick; Unipolar response anchors: 0 (Definitely not) to 100 (Definitely so).
Measured: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Alertness/Drowsiness
Visual analog scale (VAS) rating; Question text: My mental state is...; Bipolar response anchors: 0 (Very drowsy), 50 (Neither drowsy nor alert), 100 (Very alert).
Measured: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Floating
Visual analog scale (VAS) rating; Question text: I feel as if I am floating; Unipolar response anchors: 0 (Not at all) to 100 (Very much).
Measured: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Detached
Visual analog scale (VAS) rating; Question text: I feel detached from my body; Unipolar response anchors: 0 (Not at all) to 100 (Very much).
Measured: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Overall Drug Liking
Visual analog scale (VAS) rating; Question text: Overall, my liking for this drug is ...; Bipolar response anchors: 0 (Strong disliking), 50 (Neither like nor dislike), 100 (Strong liking)
Measured: At 12, 24, and 56 hours aft drug intake
Drug Similarity
Visual analog scale (VAS) rating; Questions 1-15: How similar is the drug you most recently received to...? with 15 drugs to be assessed and response anchors 0 (Not at all similar) to 100 (Very similar); Question 16: How familiar was the effect of the drug you most recently received? for an overall familiarity assessment with response anchors 0 (Very unfamiliar) to 100 (Very familiar).
Measured: At 12, 24, and 56 hours aft drug intake
Morphine-Benzedrine Group (MBG) scale
The Addiction Research Center Inventory (ARCI) scale to assess euphoria (MBG scale) was presented to the participant on a computer screen as multiple choices. Participants were asked to select their responses by pointing to one of them with the mouse; the two responses are "False" or "True".
Measured: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Benzedrine Group (BG) scale
The Addiction Research Center Inventory (ARCI) scale to assess stimulant-like effects: amphetamine, A-scale and Benzedrine Group (BG scale) was presented to the participant on a computer screen as multiple choices. Participants were asked to select their responses by pointing to one of them with the mouse; the two responses are "False" or "True".
Measured: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Pentobarbital-Chlorpromazine-Alcohol Group (PCAG) scale
The Addiction Research Center Inventory (ARCI) scale to assess sedation was presented to the participant on a computer screen as multiple choices. Participants were asked to select their responses by pointing to one of them with the mouse; the two responses are "False" or "True".
Measured: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Pupillometry
Pupil diameter was measured under mesopic lighting conditions. Data from a series of frames were used in the calculation, and the weighted average and standard deviation of the pupil size was calculated.
Measured: Pre-dose and at 9 distinct time points between 1 and 56 hours after drug intake
Divided Attention Test
Manual-tracking test with a simultaneous visual target detection component. Participant is provided with joystick and presented with the image of an airplane and a randomly curving road; participant has to position the airplane over the center of the road while being distracted repeatedly by visual targets they have to respond to. Time over the road (percentage), response latency of correct responses (milliseconds) and target hits (percentage) are recorded.
Measured: Pre-dose and at 8 distinct time points between 1 and 56 hours after drug intake
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2018
- Study start15 Apr 2013
- Primary completion8 Mar 2014
- Study completion8 Mar 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Abuse, DrugStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Nested-randomized, single site, double-blind, double-dummy, placebo- and active-controlled, crossover design with administration of a single oral dose. Based on the assigned treatment sequence, each participant was randomly allocated to receive a single oral dose of the investigational medicinal product (IMP) in each of 7 periods. One administration of placebo (Treatment G) always followed cebranopadol 800 micrograms (Treatment C). Each IMP administration was given under fasted conditions and was separated by a washout period of at least 14 days.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 226 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tris Pharma, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Grünenthal Study Director, Study director, Grünenthal GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03757559
- Sponsor's protocol ID
- HP6005/10
- Status last verified
- Jul 2021
- First submitted
- 27 Nov 2018
- Last updated
- 15 Jul 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-dose, Nested-randomized, Double-blind, Double-dummy, Placebo- and Active-controlled Crossover Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
- ClinicalTrials.gov ID
- NCT03757559
- Acronym / sponsor ID
- HP6005/10
- Conditions
- Abuse, Drug
- Keywords
- Cebranopadol, Hydromorphone, Drug liking
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 226 participants (actual)
- Lead sponsor
- Tris Pharma, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Apr 2013 (actual)
- Primary completion
- 8 Mar 2014 (actual)
- Study completion
- 8 Mar 2014 (actual)
- First posted
- 29 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study was to evaluate the abuse potential of single doses of cebranopadol (GRT6005) relative to hydromorphone (immediate-release formulation [IR] and placebo in 48 non-dependent recreational opioid users.
Secondary objectives were to evaluate the abuse potential of hydromorphone IR compared to placebo (trial validation), to evaluate the safety and tolerability of single doses of cebranopadol (200, 400, and 800 micrograms), and to evaluate pharmacokinetics (PK) of cebranopadol and optionally some of its metabolites.
Detailed description
The study comprised an Enrollment Visit, a Qualification Phase, a Treatment Phase with 7 double-blind treatment periods for each participant, and a Final Examination.
In the Qualification Phase, all participants completed a naloxone challenge test to confirm that they were not opioid-dependent. The Objective Opioid Withdrawal Scale was used to record the signs or symptoms of withdrawal observed during the naloxone challenge test. Following the naloxone challenge test, participants received a single oral dose of hydromorphone immediate-release (IR) 12 milligrams (mg) and placebo in a double-blinded, randomized crossover manner to ensure that they could discriminate between an active drug and placebo and could tolerate hydromorphone IR 12 mg. After a washout phase of at least 3 days, participants could continue with the Treatment Phase.
In the Treatment Phase, each participant received single oral doses of the 7 different investigational medicinal products (IMPs) (Treatment A to Treatment G) in 7 sequential treatment periods. The treatment sequences per participant were randomly assigned, except for one administration of placebo (Treatment G) which always followed the highest dose of cebranopadol (Treatment C). Each IMP administration was given under fasted conditions and was separated by a washout period of at least 14 days.
Participants were confined to the study site from Day -1 until 48 hours after the first IMP administration in the Qualification Phase and from Day -1 until 56 hours after the IMP administration in the treatment periods. Pharmacodynamic assessments and blood sampling for pharmacokinetics were performed from pre-dose until 56 hours post-dose in each treatment period.
The Final Examination was conducted 5 days to 10 days after the discharge from the last treatment period or upon early discontinuation from the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 7
- Model description
- Nested-randomized, single site, double-blind, double-dummy, placebo- and active-controlled, crossover design with administration of a single oral dose. Based on the assigned treatment sequence, each participant was randomly allocated to receive a single oral dose of the investigational medicinal product (IMP) in each of 7 periods. One administration of placebo (Treatment G) always followed cebranopadol 800 micrograms (Treatment C). Each IMP administration was given under fasted conditions and was separated by a washout period of at least 14 days.
| Arm | Type | Receives |
|---|---|---|
| Cebranopadol 200 micrograms (Treatment A) | Experimental | Drug: Cebranopadol 100 micrograms, Drug: Placebo matching hydromorphoneCebranopadol 200 micrograms (low dose): Participants took 2 tablets (cebranopadol 100 micrograms) as a single dose. In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose. |
| Cebranopadol 400 micrograms (Treatment B) | Experimental | Drug: Cebranopadol 400 micrograms, Drug: Placebo matching hydromorphoneCebranopadol 400 micrograms (medium dose): Participants took 2 tablets (cebranopadol 400 micrograms plus matching placebo) as a single dose. In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose. |
| Cebranopadol 800 micrograms (Treatment C) | Experimental | Drug: Cebranopadol 400 micrograms, Drug: Placebo matching hydromorphoneCebranopadol 800 micrograms (high dose): Participants took 2 tablets containing cebranopadol 400 micrograms as a single dose. In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose. |
| Hydromorphone IR 8 milligrams (Treatment D) | Active comparator | Drug: Hydromorphone hydrochloride 4 milligrams, Drug: Placebo matching cebranopadolHydromorphone immediate-release (IR) 8 milligrams: Participants took 4 capsules (2 capsules of hydromorphone hydrochloride 4 mg plus 2 placebo capsules) as a single dose. In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose. |
| Hydromorphone IR 16 milligrams (Treatment E) | Active comparator | Drug: Hydromorphone hydrochloride 4 milligrams, Drug: Placebo matching cebranopadolHydromorphone immediate-release (IR) 16 milligrams: Participants took 4 capsules of hydromorphone hydrochloride 4 mg as a single dose. In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose. |
| Placebo (Treatment F) | Placebo comparator | Drug: Placebo matching hydromorphone, Drug: Placebo matching cebranopadolPlacebo: Participants took 4 placebo capsules matching hydromorphone capsules as a single dose. In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose. |
| Placebo (Treatment G) | Placebo comparator | Drug: Placebo matching hydromorphone, Drug: Placebo matching cebranopadolPlacebo (following Treatment C): Participants took 2 placebo tablets matching cebranopadol tablets as a single dose. In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Informed consent signed.
- Male and female, aged 18 years to 55 years, inclusive.
- History of recreational opioid use (defined as non-therapeutic use at least 10 times in the participant's lifetime and at least once in the last 12 weeks prior to the Enrollment Visit).
- Body mass index between 19 kilograms per square meter and 32 kilograms per square meter inclusive, with a body weight of not less than 50 kilograms at enrollment.
- Participants must be in good health as determined by medical history, physical examination, 12-lead electrocardiogram (ECG), and vital signs (pulse rate, systolic blood pressure and diastolic blood pressure, respiratory rate, and oxygen saturation using pulse oximetry) at enrollment.
Key exclusion criteria (55 listed)
- Current substance dependence (except nicotine and caffeine dependence) as defined by the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV).
- Unwillingness or inability to abstain from recreational drug use for the duration of the study.
- Positive or missing alcohol breath test at enrollment.
- Participants attempting to discontinue their recreational drug use or who had been in a drug rehabilitation program in the 12 months prior to enrollment.
- Current consumption of more than 20 cigarettes per day or inability to abstain from smoking (or use of any nicotine-containing substance) for at least 26 hours.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cebranopadol 100 microgramsTablets were taken under fasted conditions with non-carbonated water. | Drug | Cebranopadol 200 micrograms (Treatment A) |
| Cebranopadol 400 microgramsTablets were taken under fasted conditions with non-carbonated water. | Drug | Cebranopadol 400 micrograms (Treatment B), Cebranopadol 800 micrograms (Treatment C) |
| Hydromorphone hydrochloride 4 milligramsAlso: Dilaudid (Trade Mark) 4 mgOver-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water. | Drug | Hydromorphone IR 16 milligrams (Treatment E), Hydromorphone IR 8 milligrams (Treatment D) |
| Placebo matching hydromorphonePlacebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water. | Drug | Cebranopadol 200 micrograms (Treatment A), Cebranopadol 400 micrograms (Treatment B), Cebranopadol 800 micrograms (Treatment C), Placebo (Treatment F), Placebo (Treatment G) |
| Placebo matching cebranopadolPlacebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water. | Drug | Hydromorphone IR 16 milligrams (Treatment E), Hydromorphone IR 8 milligrams (Treatment D), Placebo (Treatment F), Placebo (Treatment G) |
Primary outcome
Drug Liking (at this moment)
Time frame: At 16 distinct time points between 30 minutes and 56 hours after drug intake
Visual analog scale (VAS) rating; Question text: At this moment, my liking for this drug is ...; Bipolar response anchors: 0 (Strong disliking), 50 (Neither like nor dislike), 100 (strong liking).
16 secondary outcomes
Any Drug Effects
Time frame: At 16 distinct time points between 30 minutes and 56 hours after drug intake
Good Drug Effects
Time frame: At 16 distinct time points between 30 minutes and 56 hours after drug intake
Bad Drug Effects
Time frame: At 16 distinct time points between 30 minutes and 56 hours after drug intake
High
Time frame: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Take Drug Again
Time frame: At 12, 24, and 56 hours aft drug intake
Feeling Sick
Time frame: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Alertness/Drowsiness
Time frame: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Floating
Time frame: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Detached
Time frame: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Overall Drug Liking
Time frame: At 12, 24, and 56 hours aft drug intake
Drug Similarity
Time frame: At 12, 24, and 56 hours aft drug intake
Morphine-Benzedrine Group (MBG) scale
Time frame: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Benzedrine Group (BG) scale
Time frame: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Pentobarbital-Chlorpromazine-Alcohol Group (PCAG) scale
Time frame: Pre-dose and at 16 distinct time points between 30 minutes and 56 hours after drug intake
Pupillometry
Time frame: Pre-dose and at 9 distinct time points between 1 and 56 hours after drug intake
Divided Attention Test
Time frame: Pre-dose and at 8 distinct time points between 1 and 56 hours after drug intake
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2021.
- Individual participant dataSharing planned: No
Related trials for Abuse, Drug
Recruiting
The Trans-Led Care Study
Substance Abuse, Substance Addiction
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Recruiting
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
Drug Abuse, Nicotine Dependence
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Active, not recruiting
The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care
Opioid Dependence, Substance Abuse Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Grünenthal Study Director study director
Grünenthal GmbH
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Cebranopadol 100 micrograms, Cebranopadol 400 micrograms and Hydromorphone hydrochloride 4 milligrams in people with Abuse, Drug, run by Tris Pharma, Inc. at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 55 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Drug Liking (at this moment) (time frame: At 16 distinct time points between 30 minutes and 56 hours after drug intake). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2021.